Avicena to Advance Huntington’s Disease Clinical Program Into Phase III

Avicena announced it had selected the optimal dose of HD-02, its novel drug candidate for the treatment of Huntington’s Disease.

The dose-escalation study evaluated HD-02 in a range of doses from 10 to 40 grams per day and determined the optimal dose that provided the maximum efficacy, safety and tolerability, the company said.

According to the company, based on these findings, a double-blind, placebo-controlled Phase III clinical trial is anticipated to commence in early 2008.